Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NASDAQ:CLYM NASDAQ:CRBP NASDAQ:CRMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$21.04+1.0%$20.36$89.95▼$99.05$609.84M0.9553,591 shs1.13 million shsCLYMClimb Bio$11.71+6.8%$9.12$1.16▼$12.48$669.66M0.09696,021 shs859,578 shsCRBPCorbus Pharmaceuticals$7.68-3.0%$9.92$6.72▼$20.56$142.22M2.57297,136 shs218,324 shsCRMDCorMedix$8.42-0.3%$7.42$6.13▼$17.43$659.92M1.461.94 million shs247,205 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics0.00%-5.27%-5.73%+41.87%+190.21%CLYMClimb Bio0.00%-0.36%+23.42%+55.02%+805.79%CRBPCorbus Pharmaceuticals0.00%-30.31%-19.94%-5.27%+8.21%CRMDCorMedix0.00%+5.76%+11.20%+17.06%-30.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$21.04+1.0%$20.36$89.95▼$99.05$609.84M0.9553,591 shs1.13 million shsCLYMClimb Bio$11.71+6.8%$9.12$1.16▼$12.48$669.66M0.09696,021 shs859,578 shsCRBPCorbus Pharmaceuticals$7.68-3.0%$9.92$6.72▼$20.56$142.22M2.57297,136 shs218,324 shsCRMDCorMedix$8.42-0.3%$7.42$6.13▼$17.43$659.92M1.461.94 million shs247,205 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics0.00%-5.27%-5.73%+41.87%+190.21%CLYMClimb Bio0.00%-0.36%+23.42%+55.02%+805.79%CRBPCorbus Pharmaceuticals0.00%-30.31%-19.94%-5.27%+8.21%CRMDCorMedix0.00%+5.76%+11.20%+17.06%-30.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/ACLYMClimb Bio 3.08Buy$20.3073.36% UpsideCRBPCorbus Pharmaceuticals 2.75Moderate Buy$42.00447.23% UpsideCRMDCorMedix 2.75Moderate Buy$15.0078.25% UpsideCurrent Analyst Ratings BreakdownLatest CRBP, CLYM, AVTE, and CRMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026CRBPCorbus Pharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$38.00 ➝ $30.005/26/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/26/2026CRBPCorbus Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.005/22/2026CRBPCorbus Pharmaceuticals MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$40.00 ➝ $44.005/15/2026CRMDCorMedix Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/14/2026CRMDCorMedix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/13/2026CRBPCorbus Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$57.00 ➝ $54.005/13/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.005/12/2026CRBPCorbus Pharmaceuticals Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$36.00 ➝ $33.005/12/2026CLYMClimb Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.005/8/2026CLYMClimb Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$15.00 ➝ $17.00(Data available from 6/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ACLYMClimb BioN/AN/AN/AN/A$3.36 per shareN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/A$8.40 per shareN/ACRMDCorMedix$311.71M2.12$2.04 per share4.13$5.14 per share1.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%N/ACLYMClimb Bio-$59.85M-$0.78N/AN/AN/AN/A-31.45%-30.39%8/11/2026 (Estimated)CRBPCorbus Pharmaceuticals-$78.54M-$5.82N/AN/AN/AN/A-70.89%-61.78%8/11/2026 (Estimated)CRMDCorMedix$163.05M$2.133.9556.10N/A45.25%45.57%24.76%8/6/2026 (Estimated)Latest CRBP, CLYM, AVTE, and CRMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CRMDCorMedix$0.35$0.43+$0.08$0.43$104.96 million$127.43 million5/12/2026Q1 2026CRBPCorbus Pharmaceuticals-$1.26-$1.23+$0.03-$1.23N/AN/A5/7/2026Q1 2026CLYMClimb Bio-$0.26-$0.20+$0.06-$0.20N/AN/A3/9/2026Q4 2025CRBPCorbus Pharmaceuticals-$1.78-$1.25+$0.53-$1.25$1.11 millionN/A3/5/2026Q4 2025CLYMClimb Bio-$0.20-$0.26-$0.06-$0.26N/AN/A3/5/2026Q4 2025CRMDCorMedix$0.86$0.16-$0.70$0.16$127.02 million$128.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ACLYMClimb BioN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78CLYMClimb BioN/A27.8627.86CRBPCorbus PharmaceuticalsN/A7.927.92CRMDCorMedix0.332.972.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/ACLYMClimb Bio69.76%CRBPCorbus Pharmaceuticals64.64%CRMDCorMedix34.18%Insider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%CLYMClimb Bio2.60%CRBPCorbus Pharmaceuticals3.50%CRMDCorMedix3.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableCLYMClimb Bio957.26 million55.77 millionN/ACRBPCorbus Pharmaceuticals4018.53 million17.88 millionOptionableCRMDCorMedix3078.45 million75.71 millionOptionableCRBP, CLYM, AVTE, and CRMD HeadlinesRecent News About These CompaniesCorMedix Inc (NASDAQ:CRMD) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 31 at 4:42 AM | americanbankingnews.comCorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long RunMay 27, 2026 | seekingalpha.comCorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift LoomsMay 22, 2026 | marketbeat.comUBS Group AG Sells 454,873 Shares of CorMedix Inc $CRMDMay 19, 2026 | marketbeat.comCorMedix: Long-Term Prospects Remain Poor Despite Q1 BeatMay 18, 2026 | seekingalpha.comDoes Strong Q1 Beat And Raised Outlook Transform The Bull Case For CorMedix (CRMD)?May 18, 2026 | finance.yahoo.comHC Wainwright Forecasts CorMedix's Q2 Earnings (NASDAQ:CRMD)May 18, 2026 | marketbeat.comA Look At CorMedix (CRMD) Valuation After Strong Q1 2026 Results And Raised Full Year GuidanceMay 16, 2026 | finance.yahoo.comCorMedix Inc $CRMD Shares Bought by Vanguard Group Inc.May 16, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Cormedix (CRMD)May 15, 2026 | theglobeandmail.comCRMD Q1 Earnings Beat on DefenCath Momentum, Guidance RaisedMay 15, 2026 | zacks.comCorMedix Inc. (NASDAQ:CRMD) Q1 2026 Earnings Call TranscriptMay 15, 2026 | insidermonkey.comCormedix Therapeutics to Participate in two Upcoming Investor ConferencesMay 15, 2026 | globenewswire.comCormedix Inc (CRMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...May 15, 2026 | finance.yahoo.comCRMD stock soared 18% today – here’s what fueled CorMedix’s triple-digit Q1 revenue surgeMay 14, 2026 | msn.comCorMedix (CRMD) Q1 2026 Earnings TranscriptMay 14, 2026 | finance.yahoo.comCorMedix (NASDAQ:CRMD) Issues Earnings ResultsMay 14, 2026 | marketbeat.comCorMedix Inc. (CRMD) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comCorMedix: Q1 Earnings SnapshotMay 14, 2026 | wtop.comWCorMedix shares jump after revenue beat and higher full-year guidanceMay 14, 2026 | msn.comCorMedix Q1 Earnings Call HighlightsMay 14, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRBP, CLYM, AVTE, and CRMD Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$21.04 +0.20 (+0.96%) As of 05/29/2026Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Climb Bio NASDAQ:CLYM$11.71 +0.75 (+6.84%) As of 11:19 AM Eastern This is a fair market value price provided by Massive. Learn more.Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.Corbus Pharmaceuticals NASDAQ:CRBP$7.68 -0.24 (-2.97%) As of 11:19 AM Eastern This is a fair market value price provided by Massive. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.CorMedix NASDAQ:CRMD$8.41 -0.03 (-0.30%) As of 11:20 AM Eastern This is a fair market value price provided by Massive. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Alphabet Bets on Hardware With Googlebook and AI Glasses Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
